Notch pathway activation is associated with pancreatic cancer treatment failure.

[1]  Donald J L Jones,et al.  Notch3 and Hey-1 as Prognostic Biomarkers in Pancreatic Adenocarcinoma , 2012, PloS one.

[2]  H. Katagiri,et al.  Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. , 2012, American journal of clinical pathology.

[3]  A. Maitra,et al.  Heterogeneity and Targeting of Pancreatic Cancer Stem Cells , 2012, Clinical Cancer Research.

[4]  Robert Beckman,et al.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Arii,et al.  Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. , 2012, Gastroenterology.

[6]  Hui Jiang,et al.  High Expression of Delta-Like Ligand 4 Predicts Poor Prognosis After Curative Resection for Pancreatic Cancer , 2012, Annals of Surgical Oncology.

[7]  Tao Chen,et al.  Notch1 promotes glioma cell migration and invasion by stimulating β‐catenin and NF‐κB signaling via AKT activation , 2012, Cancer science.

[8]  Masao Tanaka,et al.  Transforming Growth Factor &bgr;1 Contributes to the Invasiveness of Pancreatic Ductal Adenocarcinoma Cells Through the Regulation of CD24 Expression , 2011, Pancreas.

[9]  Le Xu,et al.  High Jagged1 expression predicts poor outcome in clear cell renal cell carcinoma. , 2011, Japanese journal of clinical oncology.

[10]  R. Qin,et al.  Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in “Stem-Cell-Like” Tumor Cells , 2011, Digestive Diseases and Sciences.

[11]  S. Ivy,et al.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.

[12]  T. Dønnem,et al.  Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer , 2010, Cancer.

[13]  C. Heeschen,et al.  Pancreatic cancer stem cells – update and future perspectives , 2010, Molecular oncology.

[14]  H. An,et al.  Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma , 2010, Cancer science.

[15]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[16]  K. Ohuchida,et al.  Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells , 2010, Cancer.

[17]  A. Jubb,et al.  Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. , 2010, The American journal of pathology.

[18]  C. Iacobuzio-Donahue,et al.  Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. , 2010, Journal of the National Cancer Institute.

[19]  M. Mullendore,et al.  Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer , 2009, Clinical Cancer Research.

[20]  Zhiwei Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. , 2009, Cancer research.

[21]  D. Simeone.  Pancreatic Cancer Stem Cells: Implications for the Treatment of Pancreatic Cancer , 2008, Clinical Cancer Research.

[22]  Xin Ma,et al.  Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. , 2008, The Journal of urology.

[23]  R. Labianca,et al.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.

[24]  G. Gallick,et al.  Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.

[25]  M. Mimeault,et al.  Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications , 2007, Cancer and Metastasis Reviews.

[26]  I. Rooman,et al.  Expression of the Notch signaling pathway and effect on exocrine cell proliferation in adult rat pancreas. , 2006, The American journal of pathology.

[27]  Zhimin Wei,et al.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. , 2005, World journal of gastroenterology.

[28]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[29]  David M. Berman,et al.  Tissue repair and stem cell renewal in carcinogenesis , 2004, Nature.

[30]  S. Varambally,et al.  JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.

[31]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Jing Zhang,et al.  Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. , 2012, Cancer letters.

[33]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.